🩺 Their goal is to create an autologous stem cell therapy that generates new blood vessels, offering a promising alternative to traditional surgeries.
🔬 This collaboration leverages Cellino’s innovative Nebula platform for scalable cell production.
🌏 Initial human trials are underway in South Korea, with expansion plans for the U.S. market.
Introduction:
The article discusses a strategic partnership between Cellino, a biotechnology firm specializing in autonomous biomanufacturing for personalized regenerative medicine, and Karis Bio, a South Korean cell therapy company. This collaboration aims to develop an autologous induced pluripotent stem cell (iPSC)-based therapy targeting cardiovascular diseases, specifically peripheral artery disease and coronary artery disease, expanding Cellino’s reach into the Asia-Pacific region.
- Cellino and Karis Bio are partnering to advance an autologous iPSC-based therapy for cardiovascular diseases, marking a significant step in regenerative medicine.
- Karis Bio’s therapy utilizes patient-specific iPSCs to create new blood vessels, providing a potential alternative to conventional surgical options.
- The agreement will utilize Cellino’s Nebula platform for scalable and high-quality production of autologous cells, enhancing manufacturing consistency.
- Karis Bio is currently conducting a first-in-human clinical trial of its iPSC therapy in South Korea, with plans for Phase II trials in the U.S.
- The collaboration aims to leverage the strengths of both companies to propel innovations in patient-specific cardiovascular therapies, as articulated by Karis Bio’s CEO.
Conclusion:
This partnership highlights a significant advancement in the field of regenerative medicine and iPSC technology, with the potential to transform treatment options for cardiovascular diseases. The collaboration aims not only to improve the production processes of autologous therapies but also to pioneer new possibilities in personalized medicine, potentially reducing the risks associated with traditional surgical interventions. Future research and trials could significantly shape the landscape of cardiovascular disease treatment.
